Immuneering Corporation (NASDAQ:IMRX) Given Consensus Rating of “Moderate Buy” by Analysts

Immuneering Corporation (NASDAQ:IMRX) has been given a consensus rating of “Moderate Buy” by the seven brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $16.50.

A number of analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research note on Monday, December 29th. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of Immuneering in a research note on Monday, March 9th. Finally, Wall Street Zen upgraded shares of Immuneering from a “sell” rating to a “hold” rating in a report on Saturday, March 7th.

Immuneering Trading Up 3.3%

NASDAQ IMRX opened at $5.02 on Monday. Immuneering has a 1-year low of $1.10 and a 1-year high of $10.08. The stock has a 50-day moving average of $4.97 and a 200-day moving average of $6.10. The firm has a market cap of $324.54 million, a PE ratio of -3.64 and a beta of 0.46.

Immuneering (NASDAQ:IMRX) last posted its quarterly earnings results on Friday, March 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.13. As a group, equities research analysts forecast that Immuneering will post -1.86 earnings per share for the current fiscal year.

Insider Transactions at Immuneering

In other news, Director Peter Feinberg bought 20,000 shares of the company’s stock in a transaction dated Monday, January 12th. The stock was bought at an average cost of $4.35 per share, for a total transaction of $87,000.00. Following the completion of the acquisition, the director owned 135,441 shares in the company, valued at approximately $589,168.35. This trade represents a 17.32% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Thomas J. Schall bought 21,645 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was acquired at an average cost of $4.67 per share, for a total transaction of $101,082.15. Following the completion of the purchase, the director directly owned 74,530 shares of the company’s stock, valued at $348,055.10. The trade was a 40.93% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 51,819 shares of company stock worth $234,472 in the last 90 days. Corporate insiders own 22.90% of the company’s stock.

Institutional Investors Weigh In On Immuneering

Institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC bought a new stake in shares of Immuneering in the 1st quarter worth approximately $32,000. Geode Capital Management LLC increased its stake in shares of Immuneering by 2.0% during the second quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock valued at $776,000 after buying an additional 4,458 shares during the period. Kingsview Wealth Management LLC bought a new position in shares of Immuneering during the second quarter valued at approximately $47,000. XTX Topco Ltd purchased a new stake in Immuneering in the second quarter worth $90,000. Finally, Bridgeway Capital Management LLC lifted its stake in Immuneering by 57.9% in the second quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company’s stock worth $322,000 after acquiring an additional 35,000 shares during the period. Hedge funds and other institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.